Cardiovascular and Chronic Liver Disease Cell Therapy Clinical Studies
Approved in Japan
SAN DIEGO -- October 25, 2012
Cytori Therapeutics (NASDAQ: CYTX) today announced two independent
investigator-sponsored and funded cell therapy clinical studies in Japan have
been approved by the Ministry of Health, Labor and Welfare under the
Guidelines on Clinical Research Using Human Stem Cells. One study will
investigate the use of Cytori’s cell therapy as a treatment for ischemic heart
failure and the other as a treatment for cirrhosis of the liver. The studies
will be performed by Shuichi Kaneko, M.D., Ph.D., Professor and Chairman of
Departments of Gastroenterology, and Disease Control and Hemostasis, Graduate
School of Medicine at Kanazawa University Hospital School of Medicine.
In each study, patients will receive an injection of Cytori’s cell therapy,
which consists of their own adipose-derived stem and regenerative cells
(ADRCs) processed at the point-of-care using the Cytori’s proprietary and
automated Celution® System. The ischemic heart failure study will enroll
patients with low left ventricular function due to a prior heart attack and
the ADRCs will be delivered through the coronary artery. In the study of
patients with cirrhosis of the liver, the ADRCs will be delivered through the
Cytori Therapeutics, Inc. is developing cell therapies based on autologous
adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and
repair soft tissue defects. Our scientific data suggest ADRCs improve blood
flow, moderate the immune response and keep tissue at risk of dying alive. As
a result, we believe these cells can be applied across multiple "ischemic"
conditions. These therapies are made available to the physician and patient at
the point-of-care by Cytori's proprietary technologies and products, including
the Celution® system product family. www.cytori.com
Cytori Therapeutics, Inc.
Tom Baker, +1-858-875-5258
Megan McCormick, +1-858-875-5279
Press spacebar to pause and continue. Press esc to stop.